Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer
Xu et al. performed a post-hoc analysis of a randomized phase III trial (ADJUVANT/CTONG1104) of adjuvant gefitinib therapy in the treatment of Chinese patients who had undergone complete resection for EGFR-mutant stage II-IIIA non-small cell lung cancer (NSCLC) to evaluate patterns of spatial-temporal treatment-failure (1,2). Two hundred twenty-two patients were randomized 1:1 to receive gefitinib or vinorelbine plus cisplatin (VP). Among them, 106 patients received gefitinib treatment, and 87 patients who received VP completed 4 cycles of chemotherapy. One hundred twenty-four patients experienced disease progression during a median follow-up period of 36.5 months.